- CSR Summary Not yet available
- NCT02264574
- Primary Citation
Trial Information
Generic NameIbrutinibProduct NameIMBRUVICA®Therapeutic AreaCancers and Other NeoplasmsEnrollment229% FemaleN/A% WhiteN/A
Product ClassKinase InhibitorsSponsor Protocol NumberPCYC-1130-CAData PartnerJohnson & JohnsonCondition StudiedLeukemia, Chronic LymphocyticMean/Median Age (Years)71
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0828 : Prognostic Impacts of Clinical and Molecular Characteristics of Patients with Hematologic Malignancy and Potential Mechanisms
- 2023-5534 : Quality tolerance limit and duplicated patient investigation in clinical trials
- 2023-5247 : Identifying Prognostic and Predictive Factors for Causal Exposure-Response Analysis of Ibrutinib in treatment of non-Hodgkin Lymphoma